Dong

Serial No.

10/629,261

Filed

07/28/2003

Page

2

COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS (Currently amended claims showing deletions by strikethrough or double brackets (e.g., [[4]]) and additions by underlining or double underlining)

1 (currently amended): A compound of formula (I), $(R^2R^3) - A^7 - A^8 - A^9 - A^{10} - A^{11} - A^{12} - A^{13} - A^{14} - A^{15} - A^{16} - A^{17} - A^{18} - A^{19} - A^{20} - A^{21} - A^{22} - A^{23} - A^{24} - A^{25} - A^{26} - A^{27} - A^{28} - A^{29} - A^{30} - A^{31} - A^{32} - A^{33} - A^{34} - A^{35} - A^{36} - A^{37} - A^{38} - A^{39} - R^1$ (SEQ ID NO:412),

(I)

wherein

A⁷ is L-His, Ura, Paa, Pta, Amp, Tma-His, des-amino-His, or deleted;

A8 is [[Ala,]] D-Ala, Aib, Acc, N-Me-Ala, N-Me-D-Ala or N-Me-Gly;

A9 is Glu, N-Me-Glu, N-Me-Asp or Asp;

 A^{10} is Gly, Acc, β -Ala or Aib;

A¹¹ is Thr or Ser;

A¹² is Phe, Acc, Aic, Aib, 3-Pal, 4- Pal, β-Nal, Cha, Trp or X¹-Phe;

A¹³ is Thr or Ser;

A¹⁴ is Ser or Aib:

A¹⁵ is Asp or Glu;

A¹⁶ is Val, Acc, Aib, Leu, Ile, Tle, Nle, Abu, Ala or Cha;

A¹⁷ is Ser or Thr;

A¹⁸ is Ser or Thr;

 A^{19} is Tyr, Cha, Phe, 3-Pal, 4-Pal, Acc, β -Nal or X^1 -Phe;

A²⁰ is Leu, Acc, Aib, Nle, Ile, Cha, Tle, Val, Phe or X¹-Phe;

A²¹ is Glu or Asp;

 A^{22} is Gly, Acc, β -Ala, Glu or Aib;

A²³ is Gln, Asp, Asn or Glu;

A²⁴ is Ala, Aib, Val, Abu, Tle or Acc;

 A^{25} is Ala, Aib, Val, Abu, Tle, Acc, Lys, Arg, hArg, Orn, HN-CH((CH₂)_n-N(R¹⁰-R¹¹))-C(O) or NH-CH((CH₂)_e-X³)-C(O);

 A^{26} is Lys, Arg, hArg, Orn, HN-CH((CH₂)_n-N(R¹⁰-R¹¹))-C(O) or NH-CH((CH₂)_e-X³)-C(O); A^{27} is Glu Asp, Leu, Aib or Lys;

Dong

Serial No.

10/629,261 07/28/2003

Filed Page

:

A²⁸ is Phe, Pal, β- Nal, X¹-Phe, Aic, Acc, Aib, Cha or Trp;

A²⁹ is Ile, Acc, Aib, Leu, Nle, Cha, Tle, Val, Abu, Ala or Phe;

A³⁰ is Ala, Aib or Acc;

A³¹ is Trp, β-Nal, 3-Pal, 4-Pal, Phe, Acc, Aib or Cha;

A³² is Leu, Acc, Aib, Nle, Ile, Cha, Tle, Phe, X¹-Phe or Ala;

A³³ is Val, Acc, Aib, Leu, Ile, Tle, Nle, Cha, Ala, Phe, Abu, Lys or X¹-Phe;

 A^{34} is Lys, Arg, hArg, Orn, HN-CH((CH₂)_n-N(R¹⁰-R¹¹))-C(O) or NH-CH((CH₂)_e-X³)-C(O);

A³⁵ is [[Gly,]] β-Ala, D-Ala, Gaba, Ava, NH-(CH₂)_m-C(O), Aib, Acc or a D-amino acid;

 A^{36} is L-or D-Arg, D-or L-Lys, D-or L-hArg, D-or L-Orn, HN-CH((CH₂)_n-N(R¹⁰-R¹¹))-C(O), NH-CH((CH₂)_e-X³)-C(O) or deleted;

 A^{37} is Gly, β -Ala, Gaba, Ava, Aib, Acc, Ado, Arg, Asp, Aun, Aec, NH-(CH₂)_m-C(O), HN-CH((CH₂)_n-N(R¹⁰-R¹¹))-C(O), a D-amino acid, or deleted;

 A^{38} is D-or L-Lys, D-or L-Arg, D-or L-hArg, D-or L-Orn, HN-CH((CH₂)_n-N(R¹⁰-R¹¹))-C(O), NH-CH((CH₂)_e-X³)-C(O), Ava, Ado, Aec or deleted;

A³⁹ is D-or L-Lys, D-or L-Arg, HN-CH((CH₂)_n-N(R¹⁰-R¹¹))-C(O), Ava, Ado, or Aec;

X¹ for each occurrence is independently selected from the group consisting of (C₁-C6)alkyl, OH and halo;

 R^1 is OH, NH₂, (C₁-C₃₀) alkoxy, or NH- X^2 -CH₂- Z^0 , wherein X^2 is a (C₁-C₁₂) hydrocarbon moiety, and Z^0 is H, OH, CO₂H or CONH₂;

X³ is

or -C(O)-NHR¹², wherein X^4 is, independently for each occurrence, -C(O)-, -NH-C(O)- or -CH₂-, and wherein f is , independently for each occurrence, an integer from 1 to 29 inclusive; each of R^2 and R^3 is, independently for each occurrence, H;

e is, independently for each occurrence, an integer from 1 to 4 inclusive;

Inventor : Dong
Serial No. : 10/629,261
Filed : 07/28/2003

Page :

m is, independently for each occurrence, an integer from 5 to 24 inclusive; n is, independently for each occurrence, an integer from 1 to 5, inclusive; each of R^{10} and R^{11} is, independently for each occurrence, H, (C_1-C_{30}) alkyl, (C_1-C_{30}) acyl, (C_1-C_{30}) alkylsulfonyl, $-C((NH)(NH_2))$ or

; and

 R^{12} and R^{13} each is, independently for each occurrence, (C₁-C₃₀)alkyl; provided that:

- (i) when A^7 is Ura, Paa or Pta, then R^2 and R^3 are deleted;
- (ii) when R^{10} is (C_1-C_{30}) acyl, (C_1-C_{30}) alkylsulfonyl, $-C((NH)(NH_2))$ or

-C(O)-CH₂-N-(CH₂)_f-CH₃, then
$$R^{11}$$
 is H or (C₁-C₃₀)alkyl;

- (iii) at least one amino acid of a compound of formula (I) is not the same as the native sequence of hGLP-1(7-36, <u>-34, -35, -37</u> or -38)NH₂ or hGLP-1(7-36, <u>-34, -35, -37</u> or -38)OH;
- (iv) a compound of formula (I) is not an analogue of hGLP-1(7-36, -37 or -38)NH₂ or hGLP-1(7-36, -37 or -38)OH wherein a single position has been substituted by Ala;
- (v) a compound of formula (I) is not $(Arg^{26,34}, Lys^{38})hGLP-1(7-38)-E$, $(Lys^{26}(N^{\epsilon}-alkanoyl))hGLP-1(7-36, -37 \text{ or } -38)-E$, $(Lys^{34}(N^{\epsilon}-alkanoyl))hGLP-1(7-36, -37 \text{ or } -38)-E$, $(Lys^{26,34}-bis(N^{\epsilon}-alkanoyl))hGLP-1(7-36, -37 \text{ or } -38)-E$, $(Arg^{26,34}, Lys^{34}(N^{\epsilon}-alkanoyl))hGLP-1(8-36, -37 \text{ or } -38)-E$, $(Arg^{26,34}, Lys^{36}(N^{\epsilon}-alkanoyl))hGLP-1(7-36, -37 \text{ or } -38)-E$ or $(Arg^{26,34}, Lys^{38}(N^{\epsilon}-alkanoyl))hGLP-1(7-38)-E$, wherein E is -OH or -NH₂;
- (vi) a compound of formula (I) is not (Z^1)-hGLP-1(7-36, -37 or -38)-OH, (Z^1)-hGLP-1(7-36, -37 or -38)-NH₂, wherein Z^1 is selected from the group consisting of:

(c) at least one of (Aib⁸), (D-Ala⁸) and (Asp⁹); and

Dong

Serial No.

10/629,261 07/28/2003

Filed Page

5

(d) $(Tyr^{7});$

- (vii) a compound of formula (I) is not a combination of any two of the substitutions listed in groups (vi)(a) to (vi)(d); and
- (viii) a compound of formula (I) is not (N-Me-Ala⁸)hGLP-1(8-36 or -37), (Glu¹⁵)hGLP-1(7-36 or -37), (Asp²¹)hGLP-1(7-36 or -37), (Phe³¹)hGLP-1(7-36 or -37); or a pharmaceutically acceptable salt thereof.
- 2 (original): A compound according to claim 1, wherein A^{11} is Thr; A^{13} is Thr; A^{15} is Asp; A^{17} is Ser; A^{18} is Ser; A^{21} is Glu; A^{23} is Gln or Glu; A^{27} is Glu; A^{31} is Trp; or a pharmaceutically acceptable salt thereof.
- 3 (original): A compound according to claim 2, wherein A^9 is Glu, N-Me-Glu or N-Me-Asp; A^{12} is Phe, Acc or Aic; A^{16} is Val, Acc or Aib; A^{19} is Tyr; A^{20} is Leu, Acc or Cha; A^{24} is Ala, Aib or Acc; A^{25} is Ala, Aib, Acc, Lys, Arg, hArg, Orn, HN-CH((CH₂)_n-N(R¹⁰R¹¹))-C(O) or HN-CH((CH₂)_e-X³)-C(O); A^{28} is Phe; A^{29} is Ile or Acc; A^{30} is Ala or Aib; A^{32} is Leu, Acc or Cha; and A^{33} is Val or Acc; or a pharmaceutically acceptable salt thereof.
- 4 (currently amended): A compound according to claim 3, wherein A^8 is [[Ala,]] D-Ala, Aib, A6c, A5c, N-Me-Ala, N-Me-D-Ala or N-Me-Gly; A^{10} is Gly; A^{12} is Phe, A6c or A5c; A^{16} is Val, A6c or A5c; A^{20} is Leu, A6c, A5c or Cha; A^{22} is Gly, β -Ala or Aib; A^{24} is Ala or Aib; A^{29} is Ile, A6c or A5c; A^{32} is Leu, A6c, A5c or Cha; A^{33} is Val, A6c or A5c; A^{35} is Aib, β -Ala, Ado, A6c, A5c or Gly; and A^{37} is Gly, Aib, β -Ala, Ado, D-Ala or deleted; or a pharmaceutically acceptable salt thereof.
- 5 (original): A compound according to claim 4 or a pharmaceutically acceptable salt thereof, wherein X^4 for each occurrence is -C(O)-; e for each occurrence is independently 1 or 2; and R^1 is OH or NH_2 .
- 6 (withdrawn) A compound according to claim 5 or a pharmaceutically acceptable salt thereof, wherein R^2 is H and R^3 is (C_1-C_{30}) alkyl, (C_2-C_{30}) alkenyl, (C_1-C_{30}) acyl,

Dong

Serial No.

10/629,261 07/28/2003

Filed Page

6

(C₁-C₃₀)alkylsulfonyl,

7 (original): A compound according to claim 5 or a pharmaceutically acceptable salt thereof, wherein R^{10} is (C_1-C_{30}) acyl, (C_1-C_{30}) alkylsulfonyl or

-C(O)-CH
$$_2$$
—N—(CH $_2$) $_f$ -CH $_3$, and R 11 is H.

8 (original): A compound according to claim 7 or a pharmaceutically acceptable salt thereof, wherein R^{10} is (C_4-C_{20}) acyl, (C_4-C_{20}) alkylsulfonyl or

9 (previously presented): A compound according to claim 1 wherein said compound is:

(Aib⁸, β -Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:5),

(Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^{ϵ}-tetradecanoyl))hGLP-1(7-36)NH₂(SEQ ID NO:6),

(Aib^{8,35}, Arg²⁶, Lys³⁴(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:7),

(Aib^{8,35,37}, Arg^{26,34}, Lys³⁸(N $^{\epsilon}$ -tetradecanoyl))hGLP-1(7-38)NH₂(SEQ ID NO:8),

(Aib^{8,35}, Arg^{26,34}, Lys³⁶(N $^{\epsilon}$ -decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:9),

(Aib^{8,35}, Arg^{26,34}, Lys³⁶(N $^{\epsilon}$ -dodecanesulfonyl))hGLP-1(7-36)NH₂ (SEQ ID NO:10),

(Aib^{8,35}, Arg^{26,34}, Lys³⁶(N $^{\epsilon}$ -(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:11),

(Aib^{8,35}, Arg^{26,34}, Asp³⁶(1-(4-tetradecyl-piperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:12), (Aib^{8,35}, Arg^{26,34}, Asp³⁶(1-tetradecylamino))hGLP-1(7-36)NH₂ (SEQ ID NO:13),

Dong

Serial No.

10/629,261 07/28/2003

Filed Page

7

(Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^{ϵ}-tetradecanoyl), β -Ala³⁷)hGLP-1(7-37)-OH (SEQ ID NO:14) or (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^{ϵ}-tetradecanoyl))hGLP-1(7-36)-OH (SEQ ID NO:15), or a pharmaceutically acceptable salt thereof.

10 (previously presented): A compound according to claim 9 wherein said compound is (Aib⁸, β -Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:5), (Aib^{8,35}, Arg²⁶, Lys³⁴(N^{\epsilon}-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:7), (Aib^{8,35}, Arg^{26,34}, Lys³⁸(N^{\epsilon}-tetradecanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:8), (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^{\epsilon}-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:9), or (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^{\epsilon}-tetradecanoyl), β -Ala³⁷)hGLP-1(7-37)-OH (SEQ ID NO:14), or a pharmaceutically acceptable salt thereof.

- 11 (currently amended): A pharmaceutical composition comprising an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.
- 12 (withdrawn): A method of eliciting an agonist effect from a GLP-1 receptor in a subject in need thereof which comprises administering to said subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
- 13 (withdrawn): A method for treating a disease selected from the group consisting of Type I diabetes, Type II diabetes, obesity, glucagonomas, secretory disorders of the airway, metabolic disorder, arthritis, osteoporosis, central nervous system disease, restenosis and neurodegenerative disease, in a subject in need thereof which comprises administering to said subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
 - 14 (withdrawn): A method according to claim 13 wherein said disease is Type I

Inventor : Dong
Serial No. : 10/629,261
Filed : 07/28/2003
Page : 8

diabetes or Type II diabetes.

15 (currently amended): A compound according to claim 1 wherein said compound

```
is:
(Aib<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ-ID-NO:71);
(β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:72);
(Aib<sup>8</sup>, A6c<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEO ID NO:77);
(Aib<sup>8</sup>, A5c<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:78);
(Aib<sup>8</sup>, D-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:79);
(Aib<sup>8,35</sup>, A6c<sup>32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:16);
(Aib<sup>8,35</sup>, A5c<sup>32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:80);
(Aib<sup>8,35</sup>, Glu<sup>23</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:17);
(Aib 8,24,35)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:18);
(Aib 8,30,35)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:81);
(Aib 8,25,35)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:82);
(Aib<sup>8,35</sup>, A6c<sup>16,20</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEO ID NO:83):
(Aib<sup>8,35</sup>, A6c<sup>16,29,32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEO ID NO:84):
(Aib<sup>8,35</sup>, A6c<sup>20,32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:85);
(Aib<sup>8,35</sup>, A6c<sup>20</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:86);
(Aib<sup>8,35</sup>, Lys<sup>25</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEO ID NO:87);
(Aib<sup>8,24,35</sup>, A6c<sup>20</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEO ID NO:88):
(Aib<sup>8,35</sup>, A6c<sup>29,32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:89);
(Aib<sup>8,24,35</sup>, A6c<sup>29,32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:90);
(Aib<sup>8,35</sup>, A6c<sup>12</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEO ID NO:91):
(Aib<sup>8,35</sup>, Cha<sup>20</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:92);
(Aib<sup>8,35</sup>, A6c<sup>33</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:93);
(Aib<sup>8,35</sup>, A6c<sup>20,32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:85);
(Aib<sup>8</sup>, A6c<sup>16,20</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:94);
(Aib<sup>8,35</sup>, β-Ala<sup>22</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEO ID NO:95):
(Aib<sup>8,22,35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEO ID NO:96):
```

```
Filed
                                      07/28/2003
 Page
 (Aib<sup>8,35</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:19);
 (Aib<sup>8,24,35</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:97);
 (Aib<sup>8,24,25,35</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:98);
 (Aib<sup>8,24,25,35</sup>, A6c<sup>16,20,32</sup>, Glu<sup>23</sup>,)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:99);
 (Aib<sup>8</sup>, A6c<sup>32</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:100);
 (Aib<sup>8</sup>, A5c<sup>32</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:101);
 (Aib<sup>8</sup>, Glu<sup>23</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:20);
 (Aib<sup>8,24</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:102);
 (Aib<sup>8,30</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:103);
 (Aib<sup>8,25</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:104);
 (Aib<sup>8</sup>, A6c<sup>16,20</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:94);
(Aib<sup>8</sup>, A6c<sup>16,29,32</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:105);
(Aib<sup>8</sup>, A6c<sup>20,32</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:106);
(Aib<sup>8</sup>, A6c<sup>20</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:107);
(Aib<sup>8</sup>, Lys<sup>25</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:108);
(Aib<sup>8,24</sup>, A6c<sup>20</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:109);
(Aib<sup>8</sup>, A6c<sup>29,32</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:110);
(Aib<sup>8,24</sup>, A6c<sup>29,32</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:111);
(Aib<sup>8</sup>, A6c<sup>12</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:112);
(Aib<sup>8</sup>, Cha<sup>20</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:113);
(Aib<sup>8</sup>, A6c<sup>33</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:114);
(Aib<sup>8</sup>, A6c<sup>20,32</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:106);
(Aib<sup>8</sup>, \beta-Ala<sup>22,35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:115);
(Aib<sup>8,22</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:116);
(Aib<sup>8</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:117);
(Aib<sup>8,24</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:118);
(Aib<sup>8,24</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>, Lys<sup>34</sup>(N<sup>ε</sup>-octanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:119);
```

(Aib^{8,24,25}, Glu²³, A6c³², β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:120);

Inventor

Serial No.

Dong

```
Filed
                                    07/28/2003
Page
(Aib<sup>8,24,25</sup>, A6c<sup>16,20,32</sup>, Glu<sup>23</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:121);
(Aib<sup>8,35</sup>, D-Arg<sup>36</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:122);
(Aib<sup>8,35</sup>, D-Lys<sup>36</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:123);
(Aib<sup>8</sup>, β-Ala<sup>35</sup>, D-Arg<sup>36</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:124);
(Aib<sup>8</sup>, β-Ala<sup>35</sup>, D-Lys<sup>36</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:125);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>,)hGLP-1(7-36)NH<sub>2</sub> (SEO ID NO:21);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:126);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:127);
(Aib<sup>8</sup>, Arg<sup>25,26,34</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:128);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, \beta-Ala<sup>35</sup>, Lys<sup>36</sup>(N<sup>\epsilon</sup>-tetradecanoyl))hGLP-1(7-36)OH (SEO ID NO:129);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sup>\epsilon</sup>-tetradecanoyl))hGLP-1(7-37)OH (SEQ ID NO:130);
(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sup>\epsilon</sup>-tetradecanoyl))hGLP-1(7-37)OH (SEQ ID NO:131);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-tetradecanoyl), D-Ala<sup>37</sup>)hGLP-1(7-37)OH (SEQ ID NO:132);
(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(N^{\epsilon}-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:133);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, \beta-Ala<sup>37</sup>, Lys<sup>38</sup>(N<sup>\epsilon</sup>-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:134);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(N<sup>\varepsilon</sup>-tetradecanoyl))hGLP-1(7-38)OH (SEO ID NO:135);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sup>\epsilon</sup>-tetradecanoyl), \beta-Ala<sup>37</sup>)hGLP-1(7-37)OH (SEO ID NO:136);
(Aib<sup>8,37</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sup>\epsilon</sup>-tetradecanoyl))hGLP-1(7-37)OH (SEQ ID NO:137);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Ado<sup>37</sup>)hGLP-1(7-37)OH (SEO ID NO:138):
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Ado<sup>37</sup>)hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:139);
(Aib^8, Arg^{26,34}, Lys^{36}(N^{\epsilon}-tetradecanoyl), D-Ala^{37})hGLP-1(7-37)OH (SEO ID NO 140);
(Aib<sup>8,37</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(N<sup>\epsilon</sup>-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:141);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, \beta-Ala<sup>37</sup>, Lys<sup>38</sup>(N<sup>\epsilon</sup>-tetradecanoyl))hGLP-1(7-38)OH (SEO ID NO:142):
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(N<sup>\epsilon</sup>-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:143);
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(N<sup>\epsilon</sup>-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:144);
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(N<sup>\varepsilon</sup>-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:145);
(Aib<sup>8</sup>, Lys<sup>26</sup>(N<sup>\varepsilon</sup>-octanoyl), \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:146);
(Aib<sup>8</sup>, Lys<sup>26</sup>(N<sup>\epsilon</sup>-tetradecanoyl), \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEO ID NO:147);
(Aib<sup>8</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-hexadecanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:148);
```

Serial No.

Dong

```
Inventor
                                     Dong
 Serial No.
                                     10/629,261
 Filed
                                     07/28/2003
 Page
 (Aib<sup>8,35</sup>, Lys<sup>26</sup>(N<sup>\epsilon</sup>-octanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:149);
 (Aib<sup>8,35</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-tetradecanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:150);
 (Aib<sup>8,35</sup>, Lys<sup>26</sup>(N<sup>\epsilon</sup>-hexadecanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:151);
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-decanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:152);
(Aib<sup>8,35</sup>, Lys<sup>25</sup>, Lys<sup>26</sup>(N^{\epsilon}-octanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:153);
(Aib<sup>8,35</sup>, Lys<sup>25</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-tetradecanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEO ID NO:154);
(Aib<sup>8,35</sup>, Lys<sup>25</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-hexadecanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEO ID NO:155);
(Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Lys<sup>26</sup>(N^{\epsilon}-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:156);
(Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:157);
(Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:158);
(Aib^{8,35}, Arg^{25,34}, Lys^{26}(N^{\epsilon}-decanoyl))hGLP-1(7-36)NH_{2} (SEQ ID NO:159);
(Aib<sup>8</sup>, Lys<sup>26</sup>(N^{\epsilon}-octanoyl), Arg<sup>34</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:160);
(Aib<sup>8</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-tetradecanoyl), Arg<sup>34</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:161);
(Aib<sup>8</sup>, Lys<sup>26</sup>(N<sup>\epsilon</sup>-hexadecanoyl), Arg<sup>34</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:162);
(Aib<sup>8</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-decanoyl), Arg<sup>34</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:163);
(Aib<sup>8,35</sup>, Lys<sup>34</sup>(N<sup>ε</sup>-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:164);
(Aib<sup>8,35</sup>, Lys<sup>34</sup>(N<sup>ε</sup>-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:165);
(Aib<sup>8,35</sup>, Lys<sup>34</sup>(N<sup>\epsilon</sup>-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:166);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(N<sup>ε</sup>-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:167);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(N<sup>ε</sup>-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:168);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(N<sup>ε</sup>-decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:169);
```

(Aib^{8,35}, Arg^{25,26}, Lys³⁴(N $^{\epsilon}$ -octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:170);

 $(Aib^{8,35}, Arg^{25,26}, Lys^{34}(N^{\epsilon}-decanoyl))hGLP-1(7-36)NH_2$ (SEQ ID NO:173);

(Aib^{8,35}, Lys³⁶(N^{ϵ}-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:177);

(Aib^{8,35}, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:178);

(Aib^{8,35}, Lys²⁵, Arg²⁶, Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:174);

(Aib^{8,35}, Lys²⁵, Arg²⁶, Lys³⁴(N^e-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:175);

(Aib^{8,35}, Lys²⁵, Arg²⁶, Lys³⁴(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:176);

(Aib^{8,35}, Arg^{25,26}, Lys³⁴(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:171); (Aib^{8,35}, Arg^{25,26}, Lys³⁴(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:172);

Inventor : Dong
Serial No. : 10/629,261
Filed : 07/28/2003
Page : 12

```
(Aib<sup>8,35</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:179);
 (Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:180);
 (Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:181);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:182);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:183);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N^{\epsilon}-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:184);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(N<sup>ε</sup>-octanoyl))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:185);
(Aib^{8,35}, Arg^{26,34}, Lys^{38}(N^{\epsilon}-decanoyl))hGLP-1(7-38)NH_2 (SEQ ID NO:186);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(N^{\epsilon}-tetradecanoyl))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:187);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(N^{\epsilon}-hexadecanoyl))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:188);
(Aib<sup>8,35,37</sup>, Arg<sup>25,26,34</sup>, Lys<sup>38</sup>(N<sup>\varepsilon</sup>-octanoyl))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:189);
(Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N^\epsilon\text{-decanoyl})) hGLP-1 (7-38) NH_2 (SEQ ID NO:190);
(Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N^{\epsilon}-tetradecanoyl))hGLP-1(7-38)NH_{2} (SEQ ID NO:191);
(Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N^{\epsilon}-hexadecanoyl))hGLP-1(7-38)NH_2 (SEQ ID NO:192);
(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(N<sup>\epsilon</sup>-octanoyl))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:193);
(Aib^{8,35,37}, Arg^{26,34}, Lys^{38}(N^{\epsilon}-decanoyl))hGLP-1(7-38)NH_2 (SEQ ID NO:194);
(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(N<sup>ε</sup>-hexadecanoyl))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:195);
(Aib<sup>8,35,37</sup>, Arg<sup>25,26,34</sup>, Lys<sup>38</sup>(N<sup>\epsilon</sup>-octanoyl))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:189);
(Aib<sup>8,35,37</sup>, Arg<sup>25,26,34</sup>, Lys<sup>38</sup>(N<sup>6</sup>-decanoyl))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:190);
(Aib<sup>8,35,37</sup>, Arg2<sup>5,26,34</sup>, Lys<sup>38</sup>(N<sup>ε</sup>-tetradecanoyl))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:191);
(Aib<sup>8,35,37</sup>, Arg<sup>25,26,34</sup>, Lys<sup>38</sup>(N<sup>\epsilon</sup>-hexadecanoyl))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:192);
(Aib<sup>8,35</sup>, Lys<sup>25</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sup>\epsilon</sup>-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:196);
(Aib<sup>8,35</sup>, Lys<sup>25</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:197);
(Aib<sup>8,35</sup>, Lys<sup>25</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:198);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>36</sup>(N<sup>\epsilon</sup>-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:199);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:200);
(Aib^{8,35}, Arg^{25,26,34}, Lys^{36}(N^{\epsilon}-hexadecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:201);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:202);
(Aib<sup>8</sup>, Lys<sup>34</sup>(N<sup>ε</sup>-octanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEO ID NO:203):
(Aib<sup>8</sup>, Lys<sup>34</sup>(N<sup>\epsilon</sup>-tetradecanoyl), \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:204);
```

```
Filed
                                        07/28/2003
 Page
 (Aib<sup>8</sup>, Lys<sup>34</sup>(N<sup>\varepsilon</sup>-hexadecanoyl), \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:205);
 (Aib<sup>8</sup>, A6c<sup>32</sup>, Lys<sup>34</sup>(N<sup>\epsilon</sup>-octanoyl), \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:206);
 (Aib<sup>8</sup>, Glu<sup>23</sup>, Lys<sup>34</sup>(N<sup>\epsilon</sup>-octanoyl), \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEO ID NO:207);
 (Aib<sup>8</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>, Lys<sup>34</sup>(N<sup>ε</sup>-octanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:208);
 (Aib<sup>8</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(N<sup>\epsilon</sup>-octanoyl), \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:209);
 (Aib<sup>8</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(N<sup>\epsilon</sup>-tetradecanoyl), \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:210);
 (Aib<sup>8</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(N<sup>\epsilon</sup>-hexadecanoyl), \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:211);
 (Aib<sup>8</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(N<sup>ε</sup>-decanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:212);
 (Aib<sup>8</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>(N<sup>\epsilon</sup>-octanoyl), \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:213);
 (Aib<sup>8</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>(N^{\epsilon}-tetradecanoyl), \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:214);
 (Aib<sup>8</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>(N<sup>ε</sup>-hexadecanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:215);
 (Aib<sup>8</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>(N<sup>\epsilon</sup>-decanoyl), \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:216);
 (Aib<sup>8</sup>, Lys<sup>25</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(N<sup>\epsilon</sup>-octanoyl), \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:217);
 (Aib<sup>8</sup>, Lys<sup>25</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(N<sup>\epsilon</sup>-tetradecanoyl), \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:218);
(Aib<sup>8</sup>, Lys<sup>25</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(N<sup>ε</sup>-hexadecanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:219);
(Aib<sup>8</sup>, \beta-Ala<sup>35</sup>, Lys<sup>36</sup>(N<sup>\epsilon</sup>-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:220);
(Aib<sup>8</sup>, \beta-Ala<sup>35</sup>, Lys<sup>36</sup>(N<sup>\epsilon</sup>-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:221);
(Aib<sup>8</sup>, \beta-Ala<sup>35</sup>, Lys<sup>36</sup>(N<sup>\epsilon</sup>-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:222);
(Aib^8, Arg^{26}, \beta-Ala^{35}, Lys^{36}(N^\epsilon-octanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:223);
(Aib<sup>8</sup>, Arg<sup>26</sup>, \beta-Ala<sup>35</sup>, Lys<sup>36</sup>(N<sup>\epsilon</sup>-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:224);
(Aib<sup>8</sup>, Arg<sup>26</sup>, \beta-Ala<sup>35</sup>, Lys<sup>36</sup>(N<sup>\epsilon</sup>-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:225);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, \beta-Ala<sup>35</sup>, Lys<sup>36</sup>(N<sup>\epsilon</sup>-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:226);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, \beta-Ala<sup>35</sup>, Lys<sup>36</sup>(N<sup>\epsilon</sup>-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:227);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, \beta-Ala<sup>35</sup>, Lys<sup>36</sup>(N<sup>\epsilon</sup>-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:228);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, \beta-Ala<sup>35</sup>, Lys<sup>36</sup>(N<sup>\epsilon</sup>-decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:229);
(Aib^8, Lys^{25}, Arg^{26,34}, β-Ala^{35}, Lys^{36}(N^ε-octanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:230);
(Aib^8, Lys^{25}, Arg^{26,34}, Lys^{36}(N^ε-tetradecanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:231);
```

(Aib⁸, Lys²⁵, Arg^{26,34}, β -Ala³⁵, Lys³⁶(N^{ϵ}-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:232);

Inventor

Serial No.

Dong

```
Filed
                                    07/28/2003
 Page
 (Aib<sup>8</sup>, Arg<sup>25,26,34</sup>, \beta-Ala<sup>35</sup>, Lys<sup>36</sup>(N<sup>\epsilon</sup>-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:233);
(Aib<sup>8</sup>, Arg<sup>25,26,34</sup>, \beta-Ala<sup>35</sup>, Lys<sup>36</sup>(N<sup>\epsilon</sup>-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:234);
(Aib<sup>8</sup>, Arg<sup>25,26,34</sup>, \beta-Ala<sup>35</sup>, Lys<sup>36</sup>(N<sup>\epsilon</sup>-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:235);
(Aib<sup>8</sup>, Arg<sup>25,26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:236);
(Aib^{8,35}, Lys^{26}(N^{\epsilon}-octanoyl), A6c^{32}, Arg^{34})hGLP-1(7-36)NH<sub>2</sub> (SEO ID NO:237):
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-tetradecanoyl), A6c<sup>32</sup>, Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEO ID NO:238):
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(N<sup>\epsilon</sup>-hexadecanoyl), A6c<sup>32</sup>, Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEO ID NO:239):
(Aib<sup>8,35</sup>, A6c<sup>32</sup>, Lys<sup>34</sup>(N<sup>ε</sup>-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:240);
(Aib<sup>8,35</sup>, A6c<sup>32</sup>, Lys<sup>34</sup>(N<sup>ε</sup>-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:241);
(Aib<sup>8,35</sup>, A6c<sup>32</sup>, Lys<sup>34</sup>(N<sup>ε</sup>-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:242);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, A6c<sup>32</sup>, Lys<sup>34</sup>(N<sup>ε</sup>-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:243);
(Aib^{8,35}, Arg^{26}, A6c^{32}, Lys^{34}(N^{\epsilon}-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEO ID NO:244):
(Aib<sup>8,35</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:245);
(Aib<sup>8,35</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:246);
(Aib<sup>8,35</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:247);
(Aib^{8,35}, Arg^{26}, A6c^{32}, Lys^{36}(N^{\epsilon}-octanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:248);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(N<sup>\epsilon</sup>-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:249);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(N^{\epsilon}-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:250);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:251);
(Aib^{8,35}, Arg^{26,34}, A6c^{32}, Lys^{36}(N^{\epsilon}-decanoyl))hGLP-1(7-36)NH_{2} (SEQ ID NO:252);
(Aib^{8,35}, Arg^{26,34}, A6c^{32}, Lys^{36}(N^\epsilon\text{-tetradecanoyl})) hGLP-1 (7-36) NH_2 \ (SEQ\ ID\ NO:253);
(Aib^{8,35}, Arg^{26,34}, A6c^{32}, Lys^{36}(N^{\epsilon}-hexadecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:254);
(Aib<sup>8,24,35</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-octanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:255);
(Aib<sup>8,24,35</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-tetradecanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:256);
(Aib<sup>8,24,35</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-hexadecanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:257);
(Aib^{8,24,35}, Arg^{26}, Lys^{34}(N^{\epsilon}-octanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:258);
(Aib<sup>8,24,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(N<sup>ε</sup>-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:259);
(Aib<sup>8,24,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(N<sup>ε</sup>-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:260);
(Aib<sup>8,24,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sup>\epsilon</sup>-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:261);
(Aib<sup>8,24,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:262);
```

Serial No.

Dong

Inventor : Dong
Serial No. : 10/629,261
Filed : 07/28/2003

Page (Aib^{8,24,35}, Arg^{26,34}, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:263); (Aib^{8,24,35}, Glu²³, A6c³², Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:264); (Aib^{8,35}, Glu²³, Lys²⁶(N^ε-octanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:265); (Aib^{8,35}, Glu²³, Lys²⁶(N $^{\epsilon}$ -tetradecanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:266); (Aib^{8,35}, Glu²³, Lys²⁶(N^ε-hexadecanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEO ID NO:267); (Aib^{8,35}, Glu²³, Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:268); (Aib^{8,35}, Glu²³, A6c³², Lys³⁴(N^{ϵ}-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:269); (Aib^{8,35}, Glu²³, Arg²⁶, Lys³⁴(N $^{\epsilon}$ -octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:270); (Aib^{8,35}, Glu²³, Arg²⁶, Lys³⁴(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:271); (Aib^{8,35}, Glu²³, Arg²⁶, Lys³⁴(N $^{\epsilon}$ -hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:272); (Aib^{8,35}, Glu²³, Lys³⁶(N^{ϵ}-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:273); (Aib^{8,35}, Glu²³, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:274); (Aib^{8,35}, Glu²³, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:275); (Aib^{8,35}, Glu²³, Arg^{26,34}, Lys³⁶(N $^{\epsilon}$ -octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:276); (Aib^{8,35}, Glu²³, Arg^{26,34}, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:277); (Aib^{8,35}, Glu²³, Arg^{26,34}, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:278); (Aib^{8,30,35}, Lys²⁶(N^ε-octanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:279); (Aib^{8,30,35}, Lys²⁶(N^ε-tetradecanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:280); (Aib^{8,30,35}, Lys²⁶(N^{ϵ}-hexadecanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:281); (Aib^{8,30,35}, Arg²⁶, Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:282); (Aib^{8,30,35}, Arg²⁶, Lys³⁴(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:283); (Aib^{8,30,35}, Arg²⁶, Lys³⁴(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:284); (Aib^{8,30,35}, Arg^{26,34}, Lys³⁶(N^{ϵ}-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:285); (Aib^{8,30,35}, Arg^{26,34}, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:286); (Aib^{8,30,35}, Arg^{26,34}, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:287); (Aib^{8,35}, Glu²³, A6c³², Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:288); (Aib^{8,35}, Glu²³, A6c³², Lys³⁶(N $^{\epsilon}$ -tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:289); (Aib^{8,35}, Glu²³, A6c³², Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:290); $(Aib^{8,35}, Glu^{23}, Arg^{26,34}, A6c^{32}, Lys^{36}(N^{\epsilon}-octanoyl))hGLP-1(7-36)NH_2$ (SEQ ID NO:291);

(Aib^{8,35}, Glu²³, Arg^{26,34}, A6c³², Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:292);

Inventor : Dong
Serial No. : 10/629,261
Filed : 07/28/2003

Page: 1

```
(Aib<sup>8,35</sup>, Glu<sup>23</sup>, Arg<sup>26,34</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(N^{\epsilon}-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:293);
 (Aib<sup>8,24,35</sup>, Glu<sup>23</sup>, Arg<sup>26,34</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:294);
 (Aib^{8,24,35},\,Glu^{23},\,Arg^{26,34},\,A6c^{32},\,Lys^{36}(N^\epsilon\text{-tetradecanoyl}))hGLP-1(7-36)NH_2\,(SEQ\,\,ID\,\,NO:295);
 (Aib<sup>8,24,35</sup>, Glu<sup>23</sup>, Arg<sup>26,34</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:296);
 (Aib^{8,24,30,35}, Glu^{23}, Arg^{26,34}, A6c^{32}, Lys^{36}(N^{\epsilon}-octanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:297);
(Aib^{8,24,30,35}, Glu^{23}, Arg^{26,34}, A6c^{32}, Lys^{36}(N^{\epsilon}-tetradecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:298);
(Aib^{8,24,30,35},\,Glu^{23},\,Arg^{26,34},\,A6c^{32},\,Lys^{36}(N^{\epsilon}-hexadecanoyl))hGLP-1(7-36)NH_{2}\,(SEQ\,\,ID\,\,NO:299);
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(N<sup>\epsilon</sup>-octanesulfonyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:317);
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-dodecanesulfonyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:318);
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-hexadecanesulfonyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEO ID NO:319);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(N<sup>ε</sup>-octanesulfonyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:320);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(N<sup>ε</sup>-dodecanesulfonyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:321);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(N<sup>ε</sup>-hexadecanesulfonyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:322);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sup>\varepsilon</sup>-octanesulfonyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:323);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-hexadecanesulfonyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:324);
(Aib<sup>8,35</sup>, Asp<sup>26</sup>(1-(4-decylpiperazine)), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:325);
(Aib<sup>8,35</sup>, Asp<sup>26</sup>(1-(4-dodecylpiperazine)), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:326);
(Aib<sup>8,35</sup>, Asp<sup>26</sup>(1-(4-tetradecylpiperazine)), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:327);
(Aib<sup>8,35</sup>, Asp<sup>26</sup>(1-(4-hexadecylpiperazine)), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:328);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Asp<sup>34</sup>(1-(4-decylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:329);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Asp<sup>34</sup>(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:330);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Asp<sup>34</sup>(1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:331);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Asp<sup>34</sup>(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:332);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>36</sup>(1-(4-decylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:333);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>36</sup>(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:334);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>36</sup>(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:335);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>38</sup>(1-(4-decylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:336);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>38</sup>(1-(4-dodecylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:337);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>38</sup>(1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:338);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>38</sup>(1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:339);
```

Inventor : Dong
Serial No. : 10/629,261
Filed : 07/28/2003
Page : 17

(Aib^{8,35,37}, Arg^{26,34}, Asp³⁸(1-(4-decylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:340); (Aib^{8,35,37}, Arg^{26,34}, Asp³⁸(1-(4-dodecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:341); (Aib^{8,35,37}, Arg^{26,34}, Asp³⁸(1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:342); (Aib^{8,35,37}, Arg^{26,34}, Asp³⁸(1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:343); (Aib^{8,35}, Arg^{25,34}, Asp²⁶(1-(4-decylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:344); $(Aib^{8,35}, Arg^{25,34}, Asp^{26}(1-(4-dodecylpiperazine))) hGLP-1(7-36)NH_2 (SEQ ID NO:345);$ (Aib^{8,35}, Arg^{25,34}, Asp²⁶(1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:346); (Aib^{8,35}, Arg^{25,34}, Asp²⁶(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:347); (Aib^{8,35}, Arg^{25,26}, Asp³⁴(1-(4-decylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:348); (Aib^{8,35}, Arg^{25,26}, Asp³⁴(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:349); (Aib^{8,35}, Arg^{25,26}, Asp³⁴(1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:350); (Aib^{8,35}, Arg^{25,26}, Asp³⁴(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:351); (Aib^{8,35}, Arg^{25,26,34}, Asp³⁶(1-(4-decylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:352); (Aib^{8,35}, Arg^{25,26,34}, Asp³⁶(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:353); (Aib^{8,35}, Arg^{25,26,34}, Asp³⁶(1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:354); (Aib^{8,35}, Arg^{25,26,34}, Asp³⁶(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:355); (Aib^{8,35}, Arg^{25,26,34}, Asp³⁸(1-(4-decylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:356); (Aib^{8,35}, Arg^{25,26,34}, Asp³⁸(1-(4-dodecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:357); (Aib^{8,35}, Arg^{25,26,34}, Asp³⁸(1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:358); (Aib^{8,35}, Arg^{25,26,34}, Asp³⁸(1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:359); (Aib^{8,35,37}, Arg^{25,26,34}, Asp³⁸(1-(4-decylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:360); (Aib^{8,35,37}, Arg^{25,26,34}, Asp³⁸(1-(4-dodecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:361); (Aib^{8,35,37}, Arg^{25,26,34}, Asp³⁸(1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:362); (Aib^{8,35,37}, Arg^{25,26,34}, Asp³⁸(1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:363); (Aib^{8,35}, Arg^{26,34}, Glu³⁶(1-dodecylamino))hGLP-1(7-36)NH₂ (SEQ ID NO:364); (Aib^{8,35}, Glu²⁶(1-dodecylamino), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:365); (Aib^{8,35}, Arg²⁶, Glu³⁴(1-dodecylamino))hGLP-1(7-36)NH₂ (SEQ ID NO:366); (Aib^{8,35,37}, Arg^{26,34}, Glu³⁸(1-dodecylamino))hGLP-1(7-38)NH₂ (SEQ ID NO:367); (Aib^{8,35}, Arg³⁴, Lys²⁶(N^ε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:368);

```
Inventor : Dong
Serial No. : 10/629,261
Filed : 07/28/2003
Page : 18
```

(Aib^{8,35}, Arg³⁴, Lys²⁶(N^{ϵ}-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:369);

(Aib^{8,35}, Arg³⁴, Lys²⁶(N^ε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:370;

(Aib^{8,35}, Arg³⁴, Lys²⁶(N^ε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:371);

(Aib^{8,35}, Arg²⁶, Lys³⁴(N^{ϵ}-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:372);

(Aib^{8,35}, Arg²⁶, Lys³⁴(N^{ϵ}-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:373);

(Aib^{8,35}, Arg²⁶, Lys³⁴(N^{ϵ}-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:374);

(Aib^{8,35}, Arg²⁶, Lys³⁴(N^ε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:375);

 $(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N^{\epsilon}-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_2$ (SEQ ID NO:376);

(Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^{ϵ}-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:377);

(Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:378);

(Aib^{8,35}, Arg^{26,34}, Lys³⁸(N^{ϵ}-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:379);

(Aib^{8,35}, Arg^{26,34}, Lys³⁸(N^{ϵ}-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:380);

(Aib^{8,35}, Arg^{26,34}, Lys³⁸(N^{ϵ}-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:381);

(Aib^{8,35}, Arg^{26,34}, Lys³⁸(N^{ϵ}-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:382);

(Aib^{8,35,37}, Arg^{26,34}, Lys³⁸(N^{ϵ}-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:383);

```
Dong
   Inventor
   Serial No.
                                                                                                                   10/629,261
   Filed
                                                                                                                  07/28/2003
   Page
   (Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(N<sup>ε</sup>-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID
   NO:384);
   (Aib^{8,35,37}, Arg^{26,34}, Lys^{38}(N^{\epsilon}-(2-(4-tetradecyl-1-piperazine)-acetyl))) hGLP-1(7-38)NH_2 (SEQ\ ID)) hGLP-1(1-38)NH_2 (SEQ\ ID))
   NO:385);
  (Aib^{8,35,37}, Arg^{26,34}, Lys^{38}(N^{\epsilon}-(2-(4-hexadecyl-1-piperazine)-acetyl))) hGLP-1(7-38)NH_2 (SEQ\ ID)) hGLP-1(7-38)NH_2 (SEQ\ ID)
   NO:386);
  (Aib^{8,35}, Arg^{25,34}, Lys^{26}(N^{\epsilon}-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_2 (SEQ ID
   NO:387);
  (Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID
   NO:388);
  (Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Lys<sup>26</sup>(N^{\epsilon}-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID
  NO:389);
 (Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID
 NO:390);
(Aib<sup>8,35</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>(N^{\epsilon}-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID
  NO:391);
 (Aib<sup>8,35</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>(N^{\epsilon}-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID
 NO:392);
(Aib^{8,35}, Arg^{25,26}, Lys^{34}(N^{\epsilon}-(2-(4-tetradecyl-1-piperazine)-acetyl))) hGLP-1(7-36)NH_2 (SEQ\ ID)) hG
 NO:393);
(Aib<sup>8,35</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>(N<sup>ε</sup>-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID
 NO:394);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID
 NO:395);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID
NO:396);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>36</sup>(N<sup>\epsilon</sup>-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID
NO:397);
(Aib^{8,35}, Arg^{25,26,34}, Lys^{36}(N^\epsilon - (2-(4-hexadecyl-1-piperazine)-acetyl))) hGLP-1(7-36)NH_2 \ (SEQ\ ID-1) hGLP-1(
```

NO:398);

```
Serial No.
                                                                                                                                                                 10/629,261
       Filed
                                                                                                                                                                 07/28/2003
        Page
      (Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>38</sup>(N^{\epsilon}-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID
      NO:399);
     (Aib^{8,35}, Arg^{25,26,34}, Lys^{38}(N^\epsilon - (2-(4-dodecyl-1-piperazine)-acetyl))) hGLP-1 (7-38) NH_2 (SEQ\ ID) + (2-(4-dodecyl-1-piperazine)-acetyl)) hGLP-1 (7-38) NH_2 (SEQ\ ID) + (2-(4-dodecyl-1-piperazine)-acetyl) hGLP-1 
     NO:400);
     (Aib^{8,35}, Arg^{25,26,34}, Lys^{38}(N^\epsilon - (2-(4-tetradecyl-1-piperazine)-acetyl))) hGLP-1 (7-38) NH_2 (SEQ~ID) + (2-(4-tetradecyl-1-piperazine)-acetyl)) hGLP-1 (7-38) NH_2 (SEQ~ID) + (2-(4-tetradecyl-1-piperazine)-acetyl) hGLP-1 (7-(4-tetradecyl-1-piperazine)-acetyl) hGLP-1 (7-(4-tetradecyl-1-piperazine)-acetyl) hGLP-1 (7-(4-tetradecyl-1-piperazine)-acetyl) hGLP-1 (7-(4-tetrad
     NO:401);
    ({\rm Aib}^{8,35}, {\rm Arg}^{25,26,34}, {\rm Lys}^{38} ({\rm N}^\epsilon - (2-(4-hexadecyl-1-piperazine)-acetyl))) hGLP-1 (7-38) NH_2 (SEQ~ID) + (2-(4-hexadecyl-1-piperazine)-acetyl)) hGLP-1 (7-38) NH_2 (SEQ~ID) + (2-(4-hexadecyl-1-piperazine)-acetyl) hGLP-1 (7-(4-hexadecyl-1-piperazine)-acetyl) hGLP-1 (7-(4-hexadecyl-1-piperazine)-acetyl) hGLP-1 (7
     NO:402);
    ({\rm Aib}^{8,35,37},\,{\rm Arg}^{25,26,34},\,{\rm Lys}^{38}({\rm N}^\epsilon-(2-(4-decyl-1-piperazine)-acetyl))) hGLP-1 (7-38) NH_2 \,(SEQ\,\,{\rm ID}^2-(4-decyl-1-piperazine)-acetyl))) hGLP-1 (7-38) NH_2 \,(SEQ\,\,{\rm ID}^2-(4-decyl-1-piperazine)-acetyl)) hGLP-1 (7-38) NH_2 \,(SEQ\,\,{\rm ID}^2-(4-decyl-1-piperazine)-acetyl)) hGLP-1 (7-38) NH_2 \,(SEQ\,\,{\rm ID}^2-(4-decyl-1-piperazine)-acetyl)
     NO:403);
    (Aib^{8,35,37},\,Arg^{25,26,34},\,Lys^{38}(N^\epsilon-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH_2\,(SEQ\,ID))+(1-38)(N^\epsilon-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH_2\,(SEQ\,ID))
     NO:404);
    (Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N^{\epsilon}-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH_{2} (SEQ
     ID NO:405):
   (Aib^{8,35,37},\,Arg^{25,26,34},\,Lys^{38}(N^\epsilon-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2\,(SEQ^{-1}-1)+(1-38)NH_2
   ID NO:406);
  (Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-decanoyl))hGLP-1(7-36)OH (SEQ ID NO:407);
  (Aib<sup>8,35</sup>, Lys<sup>25</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-decanoyl))hGLP-1(7-36)OH (SEQ ID NO:408);
  (Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Ava<sup>37</sup>, Ado<sup>38</sup>)hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:409);
  (Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>37</sup>, Ava<sup>38</sup>, Ado<sup>39</sup>)hGLP-1(7-39)NH<sub>2</sub> (SEQ ID NO:27);
  (Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Aun<sup>37</sup>)hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:28);
 (Aib<sup>8,17,35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:29);
 (Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, D-Asp<sup>37</sup>, Ava<sup>38</sup>, Aun<sup>39</sup>)hGLP-1(7-39)NH<sub>2</sub> (SEQ ID NO:30);
 (Gly<sup>8</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:31);
 (Ser<sup>8</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:32);
 (Aib<sup>8</sup>, Glu<sup>22,23</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:33);
 (Gly<sup>8</sup>, Aib<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:34);
(Aib<sup>8</sup>, Lys<sup>18</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO35);
(Aib<sup>8</sup>, Leu<sup>27</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:36);
```

Dong

```
Filed
                                     07/28/2003
 Page
 (Aib<sup>8</sup>, Lys<sup>33</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:37);
 (Aib<sup>8</sup>, Lys<sup>18</sup>, Leu<sup>27</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:38);
 (Aib<sup>8</sup>, D-Arg<sup>36</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:39);
 (Aib<sup>8</sup>, \beta-Ala<sup>35</sup>, D-Arg<sup>37</sup>)hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:40);
 (Aib<sup>8,27</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:41);
 (Aib<sup>8,27</sup>, \beta-Ala<sup>35,37</sup>, Arg<sup>38</sup>)hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:42);
 (Aib<sup>8,27</sup>, \beta-Ala<sup>35,37</sup>, Arg<sup>38,39</sup>)hGLP-1(7-39)NH<sub>2</sub> (SEQ ID NO:43);
 (Aib<sup>8</sup>, Lys<sup>18,27</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:44);
 (Aib<sup>8</sup>, Lys<sup>27</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:45);
 (Aib<sup>8</sup>, β-Ala<sup>35</sup>, Arg<sup>38</sup>)hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:46);
 (Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEO ID NO:47):
(Aib<sup>8</sup>, D-Arg<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:48);
(Aib<sup>8</sup>, β-Ala<sup>35</sup>, Arg<sup>37</sup>)hGLP-1(7-37)NH<sub>2</sub> (SEO ID NO:49):
(Aib<sup>8</sup>, Phe<sup>31</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:50);
(Aib<sup>8,35</sup>, Phe<sup>31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEO ID NO:51):
(Aib<sup>8,35</sup>, Nal<sup>31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:52);
(Aib<sup>8,35</sup>, Nal<sup>28,31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:53);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Nal<sup>31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:54);
(Aib<sup>8,35</sup>, Nal<sup>19,31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:56);
(Aib<sup>8,35</sup>, Nal<sup>12,31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:57);
(Aib<sup>8,35</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:58);
(Aib<sup>8,35</sup>, Arg<sup>34</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:59);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-dodecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:60);
(Aib<sup>8</sup>, β-Ala<sup>35</sup>, Ser<sup>37</sup>(O-decanoyl))hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:61);
(Aib<sup>8,27</sup>, β-Ala<sup>35,37</sup>, Arg<sup>38</sup>, Lys<sup>39</sup>(N<sup>ε</sup>-octanoyl))hGLP-1(7-39)NH<sub>2</sub> (SEQ ID NO:62);
(Aib^8, Arg^{26,34}, β-Ala^{35}, Lys^{37}(N^ε-octanoyl))hGLP-1(7-37)NH_2 (SEQ ID NO:63);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, \beta-Ala<sup>35</sup>, Lys<sup>37</sup>(N<sup>\epsilon</sup>-decanoyl))hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:64);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, \beta-Ala<sup>35</sup>, Lys<sup>37</sup>(N<sup>\epsilon</sup>-tetradecanoyl))hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:65);
```

(Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁷(N^ε-dodecanoyl))hGLP-1(7-37)NH₂ (SEQ ID NO:410); or

Inventor

Serial No.

Dong

```
Inventor : Dong
Serial No. : 10/629,261
Filed : 07/28/2003
Page : 22
```

(Aib⁸, Arg^{26,34}, β -Ala³⁵, Lys³⁷(N^{ϵ}-dodecanoyl))hGLP-1(8-37)NH₂ (SEQ ID NO:411); or a pharmaceutically acceptable salt thereof.

16 (previously presented): A compound according to claim 15 wherein said compound is: (Aib^{8,35}, A6c³²)hGLP-1(7-36)NH₂ (SEO ID NO:16): (Aib^{8,35}, Glu²³)hGLP-1(7-36)NH₂ (SEQ ID NO:17); (Aib 8,24,35)hGLP-1(7-36)NH₂ (SEQ ID NO:18); (Aib^{8,35}, Glu²³, A6c³²)hGLP-1(7-36)NH₂ (SEQ ID NO:19); (Aib⁸, Glu²³, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:20); (Aib^{8,35}, Arg^{26,34})hGLP-1(7-36)NH₂ (SEQ ID NO:21); (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:22); (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-decanoyl))hGLP-1(7-36)OH (SEQ ID NO:23); (Aib^{8,35}, Lys²⁵, Arg^{26,34}Lys³⁶(N $^{\epsilon}$ -decanoyl))hGLP-1(7-36)OH (SEQ ID NO:24); $(Aib^8, Arg^{26,34}, β-Ala^{35}, Lys^{36}(N^ε-Aec-decanoyl))hGLP-1(7-36)NH_2$ (SEQ ID NO:25); (Aib^{8,35}, Arg^{26,34}, Ava³⁷, Ado³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:26); (Aib^{8,35}, Arg^{26,34}, Asp³⁷, Ava³⁸, Ado³⁹)hGLP-1(7-39)NH₂ (SEQ ID NO:27); (Aib^{8,35}, Arg^{26,34}, Aun³⁷)hGLP-1(7-37)NH₂ (SEQ ID NO:28); (Aib^{8,17,35})hGLP-1(7-36)NH₂ (SEQ ID NO:29); (Aib⁸, Arg^{26,34}, β-Ala³⁵, D-Asp³⁷, Ava³⁸, Aun³⁹)hGLP-1(7-39)NH₂ (SEQ ID NO:30); (Gly⁸, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:31); (Ser⁸, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:32); (Aib⁸, Glu^{22,23}, β -Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:33); (Gly⁸, Aib³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:34); (Aib⁸, Lys¹⁸, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO: 35); (Aib⁸, Leu²⁷, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEO ID NO:36): (Aib⁸, Lys³³, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:37); (Aib⁸, Lys¹⁸, Leu²⁷, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:38); (Aib⁸, D-Arg³⁶)hGLP-1(7-36)NH₂ (SEQ ID NO:39);

```
Filed
                                     07/28/2003
Page
(Aib<sup>8</sup>, β-Ala<sup>35</sup>, D-Arg<sup>37</sup>)hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:40);
(Aib<sup>8,27</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:41);
(Aib<sup>8,27</sup>, \beta-Ala<sup>35,37</sup>, Arg<sup>38</sup>)hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:42);
(Aib<sup>8,27</sup>, \beta-Ala<sup>35,37</sup>, Arg<sup>38,39</sup>)hGLP-1(7-39)NH<sub>2</sub> (SEQ ID NO:43);
(Aib<sup>8</sup>, Lys<sup>18,27</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:44);
(Aib<sup>8</sup>, Lys<sup>27</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:45);
(Aib<sup>8</sup>, β-Ala<sup>35</sup>, Arg<sup>38</sup>)hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:46);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEO ID NO:47);
(Aib<sup>8</sup>, D-Arg<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEO ID NO:48):
(Aib<sup>8</sup>, β-Ala<sup>35</sup>, Arg<sup>37</sup>)hGLP-1(7-37)NH<sub>2</sub> (SEO ID NO:49);
(Aib<sup>8</sup>, Phe<sup>31</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:50);
(Aib<sup>8,35</sup>, Phe<sup>31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEO ID NO:51):
(Aib<sup>8,35</sup>, Nal<sup>31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:52);
(Aib<sup>8,35</sup>, Nal<sup>28,31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:53);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Nal<sup>31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:54);
(Aib<sup>8,35</sup>, Nal<sup>19,31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEO ID NO:56);
(Aib<sup>8,35</sup>, Nal<sup>12,31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:57);
(Aib<sup>8,35</sup>, Lys<sup>36</sup>(N<sup>ε</sup>-decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:58);
(Aib<sup>8,35</sup>, Arg<sup>34</sup>, Lys<sup>26</sup>(N<sup>ε</sup>-decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:59);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sup>\epsilon</sup>-dodecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:60);
(Aib<sup>8</sup>, β-Ala<sup>35</sup>, Ser<sup>37</sup>(O-decanoyl))hGLP-1(7-37)-NH<sub>2</sub> (SEQ ID NO:61);
(Aib<sup>8,27</sup>, \beta-Ala<sup>35,37</sup>, Arg<sup>38</sup>, Lys<sup>39</sup>(N<sup>\epsilon</sup>-octanoyl))hGLP-1(7-39)NH<sub>2</sub> (SEQ ID NO:62);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, \beta-Ala<sup>35</sup>, Lys<sup>37</sup>(N<sup>\epsilon</sup>-octanoyl))hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:63);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, \beta-Ala<sup>35</sup>, Lys<sup>37</sup>(N<sup>\epsilon</sup>-decanoyl))hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:64); or
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>37</sup>(N<sup>ε</sup>-tetradecanoyl))hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:65);
or a pharmaceutically acceptable salt thereof.
```

Serial No.

Dong

Inventor : Dong
Serial No. : 10/629,261
Filed : 07/28/2003
Page : 24

19 (previously presented): A compound wherein said compound is:

(Aib^{8,35}, Arg^{26,34}, Phe³¹)hGLP-1(7-36)NH₂ (SEQ ID NO:55);

or a pharmaceutically acceptable salt thereof.